<DOC>
	<DOCNO>NCT01775540</DOCNO>
	<brief_summary>This study evaluate heal action eye surface artificial tear Systane® ULTRA compare two eyedrop : Maxidex Saline solution . Dry eye disease lead inflammation eye surface treat dry eye artificial tear may lead reduction inflammation improvement symptom sign .</brief_summary>
	<brief_title>Systane Ultra Versus Maxidex Versus Saline</brief_title>
	<detailed_description>For patient present office history dry eye : 1 . Consent form obtain every patient . Informed consent discuss patient detail . Every topic address separately . All risk , benefit , alternative discuss . Patient allow ask question , question answer . The assessment make conversation , whether patient understood consent describe . Each subject allow much time need review sign consent form . 2 . All patient ask fill Ocular Surface Discomfort Index ( OSDI ) questionnaire ensure meet inclusion criterion . If patient score meet eligibility requirement general ocular history take . ( Time : 10 min ) 3 . A pregnancy test give female subject child bear age . A standard eye exam perform rule ocular pathology besides refractive error . This allow confirmation study subject dry eye disease . Topical fluorescein lissamine dye use record stain cornea conjunctiva subject well tear film break-up time ( TFBUT ) . Both dye use standard-of-care eye exam around country . TFBUT first determine application sodium fluorescein onto eye use DET strip . Following triplicate evaluation TFBUT eye , ocular staining determine liquid fluorescein lissamine dye administer liquid form . ( Time 15 min ) . 4 . Patients give Alcon questionnaire fill , inquire past treatment , daily symptom distress associate dry eye disease . ( Time:15 minute ) This also serve wait period dye wash . 5 . Using graduate disposable 5 µl microcapillary tube ( Wiretol-Micropipettes , Drummond Scientific Co. , Broomall , PA , USA ) 5 µl tear / eye collect inferior temporal tear meniscus participant , without corneal anesthesia , take care ensure lid margin corneal surface touch . A maximum 5 minute allow per eye collection minimal 5 uL tear . Tears immediately dispense pre-labeled Eppendorf tube place dry ice transfer -80oC storage . ( Time : 10 minute ) 6 . A technique know Impression Cytology ( IC ) use isolate epithelial cell conjunctiva . Anesthetic drop administer eye procedure . Blunted forceps use gently press piece filter paper patient 's conjunctiva . The paper gently lift , send Mount Sinai Laboratory analysis . ( Estimated collection time : 15 minute ) . A total 6 piece per patient ( 3 piece per eye ) collect scheduled visit . For HLA-DR analysis , 2 piece eye hold room temperature vial contain fixative assay . The remain 1 piece eye pool together one vial RT-PCR assay follow order : ( 1 ) immediately merge pre-labeled Eppendorf tube 600 µL TriZol Reagent ; ( 2 ) Vortex 30 second ; ( 3 ) seal Saran Wrap ; ( 4 ) transfer -80C storage assay . 7 . Measurement Intraocular pressure use Tonopen . 8 . As part substudy intend treat patient Systane ULTRA® , Maxidex , ( FDA approve ophthalmic solution ) , saline solution placebo . Subjects assign one three group per randomization sequence correspond eye drop dispense . 9 . The patient 's response treatment assess approximately 4 week ( +/- 5 day ) use diagnostic test order ass sensitivity diagnostic test detect response medical treatment dry eye disease . In addition baseline 4 week visit , safety evaluation perform 2 week ( +/- 5 day ) visit . All procedure do baseline visit repeat except pregnancy test , tear collection impression cytology .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>A score least 15 Ocular Surface Discomfort Index ( OSDI ) symptom questionnaire . Moderate vital staining , fluorescein ( corneal evaluation , 315 NEI scale ) OR lissamine ( conjunctival evaluation , score 26 ; temporal nasal area , grade 03 ) . Willingness use study drug 4 time per day eye . Willingness discontinue use artificial tear product . Patient must provide write informed consent Patient must understand scope study include completion worksheet willing follow instruction return require study visit An intraocular pressure less equal 22 mmHg eye Contact Lens wearer Pregnant and/or lactate woman Those moderate severe Meibomian Gland Disease i.e . plug 3 gland and/or pasty secretion 3 gland presence obstruct gland total 10 gland evaluated central portion lower lid . Uncontrolled systemic ocular disease Dry eye due seasonal allergic conjunctivitis , contact lens related conjunctivitis acute seasonal diagnosis . Are monocular and/or legally blind Had ocular surgery trauma within last six month Participation ophthalmic drug device research study within 30 day prior entry study Current use eye drop artificial tear Use Restasis within three month prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>Artificial tear</keyword>
	<keyword>Ocular surface inflammation</keyword>
</DOC>